Been a long time coming but this is excellent news. Actually in the clinic now. This is the data the clinicians and FDA will want to see.
Given the large amount of data already known from old studies, this trial is a major inflection point.
The current value of the company seems to reflect the logisitc delays and percieved lack of progress rather than the value of medication and preexisting data.
Ann: First patient treated in Bisantrene trial in Israel, page-9
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
0.010(0.63%) |
Mkt cap ! $270.9M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.60 | $1.56 | $168.3K | 106.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 51 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |